Yahoo Suche Web Suche

Suchergebnisse

  1. Suchergebnisse:
  1. 7. Jan. 1991 · John Francis Seymour Jr. (born December 3, 1937) is an American retired politician who served as a United States Senator from California from 1991 to 1992. A member of the Republican Party, he was appointed to continue Pete Wilson's term but lost the special election to finish it to Democratic candidate and former San Francisco Mayor Dianne Feinstein. As of 2022, he is the most recent member ...

  2. John Francis Seymour (born December 3, 1937) is an American real estate investor and politician. Seymour attended the public schools in Mt. Lebanon, Pennsylvania. He served in the United States Marine Corps from 1955 to 1959 and graduated from the University of California, Los Angeles in 1962. Seymour was the President of the California Association of Realtors from 1978 to 1982, and worked in ...

  3. John Francis Seymour Jr. is an American retired politician who served as a United States senator from California from 1991 to 1992. A member of the Republican Party, he was appointed to continue Pete Wilson's term but lost the special election to finish it to Democratic nominee and former San Francisco mayor Dianne Feinstein.

  4. John Seymour (Q376645) From Wikidata. Jump to navigation Jump to search. United States Senator from California. edit. Language Label Description Also known as; English: John Seymour. United States Senator from California . Statements. instance of. human. ...

  5. The indolent B-cell non-Hodgkin lymphomas (B-NHL) comprise a heterogenous group of lymphoproliferative disorders characterized by slow growth kinetics and a relapsing/remitting course. Management has, until recently, been uniform across all indolent B-NHL subtypes. Improving insight into pathophysiological and molecular features of each disease ...

  6. Abstract. With the advent of highly effective novel therapies for chronic lymphocytic leukemia, conventional response assessment is not able to sensitively capture depth of response. To achieve a more precise assessment of response, minimal residual disease has been introduced to more accurately classify and quantify treatment outcomes.